This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
February 23, 2012 11:00 am ET
Christine Jacobs - Chairman and CEO
Frank Tarallo - CFO
Joe Munda - Sidoti & Company
Ezekiel Kruglick - Ardent Research
Jeff Anderson - Encore Group
Greetings and welcome to the Theragenics' fourth quarter and yearend 2011 earnings conference call. It is now my pleasure to introduce, Ms. Christine Jacobs, Chairman and CEO of Theragenics.
Good morning and welcome to Theragenics' fourth quarter and yearend 2011 conference call. Thank you for joining us today. In just a few minutes, I'll provide comments on the past quarter and 2011 and a little about the outlook for 2012. I will also talk about our just announced acquisition of the Core Oncology prostate brachytherapy customers, but first I am going to turn the call over to Frank Tarallo, our Chief Financial Officer, he's going to provide a review of the financials.
Thank you, Chris. This morning we released our consolidated financial results for the fourth quarter and yearend 2011. If you did not receive this news release or if you would like to be added to either our fax or email distribution list, please contact Investor Relations at 800-998-8479, or 770-271-0233.
Before I begin my review, please be aware that some comments made during this conference call may contain forward-looking statements involving risks and uncertainties regarding our operations and future results. Please see our press release issued today and our filings with the Securities and Exchange Commission, including without limitation, the company's Form 10-K and Forms 10-Q, which identifies specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.